Unmet needs in modern vaccinology Adjuvants to improve the immune response

被引:229
作者
Leroux-Roels, Geert [1 ]
机构
[1] Ghent Univ & Hosp, Ctr Vaccinol, B-9000 Ghent, Belgium
关键词
Adjuvants; Vaccines; HEPATITIS-B-VACCINE; PLASMODIUM-FALCIPARUM INFECTION; CROSS-REACTIVE IMMUNITY; INFLUENZA VACCINE; MALARIA VACCINE; SUBUNIT VACCINE; REACTOGENICITY PROFILE; ALUMINUM ADJUVANTS; CANCER PATIENTS; INFLUSOME-VAC;
D O I
10.1016/j.vaccine.2010.07.021
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The key objective of vaccination is the induction of an effective pathogen-specific immune response that leads to protection against infection and/or disease caused by that pathogen, and that may ultimately result in its eradication from humanity The concept that the immune response to pathogen antigens can be improved by the addition of certain compounds into the vaccine formulation was demonstrated about one hundred years ago when aluminium salts were introduced New vaccine technology has led to vaccines containing highly purified antigens with improved tolerability and safely profiles, but the immune response they induce is suboptimal without the help of adjuvants In parallel, the development of effective vaccines has been facing more and more important challenges linked to complicated pathogens (e g malaria, TB. HIV. etc) and/or to subjects with conditions that jeopardize the induction or persistence of a protective immune response A greater understanding of innate and adaptive immunity and their close interaction at the molecular level is yielding insights into the possibility of selectively stimulating immunological pathways to obtain the desired immune response The better understanding of the mechanism of 'immunogenicity' and 'adjuvanticity' has prompted the research of new vaccine design based on new technologies, such as naked DNA or live vector vaccines and the new adjuvant approaches Adjuvants can be used to enhance the magnitude and affect the type of the antigen-specific immune response. and the combination of antigens with more than one adjuvant, the so called adjuvant system approach, has been shown to allow the development of vaccines with the ability to generate effective immune responses adapted to both the pathogen and the target population This review focuses on the adjuvants and adjuvant systems currently in use in vaccines, future applications, and the remaining challenges the field is facing. (c) 2010 Elsevier Ltd All rights reserved.
引用
收藏
页码:C25 / C36
页数:12
相关论文
共 106 条
[1]   Vaccine adjuvants revisited [J].
Aguilar, J. C. ;
Rodriguez, E. G. .
VACCINE, 2007, 25 (19) :3752-3762
[2]   IMMUNOLOGICAL ADJUVANTS - DESIRABLE PROPERTIES AND SIDE-EFFECTS [J].
ALLISON, AC ;
BYARS, NE .
MOLECULAR IMMUNOLOGY, 1991, 28 (03) :279-284
[3]   Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children:: single-blind extended follow-up of a randomised controlled trial [J].
Alonso, PL ;
Sacarlal, J ;
Aponte, JJ ;
Leach, A ;
Macete, E ;
Aide, P ;
Sigauque, B ;
Milman, J ;
Mandomando, I ;
Bassat, Q ;
Guinovart, C ;
Espasa, M ;
Corachan, S ;
Lievens, M ;
Navia, MM ;
Dubois, MC ;
Menendez, C ;
Dubovsky, F ;
Cohen, J ;
Thompson, R ;
Ballou, WR .
LANCET, 2005, 366 (9502) :2012-2018
[4]   Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children:: randomised controlled trial [J].
Alonso, PL ;
Sacarlal, J ;
Aponte, JJ ;
Leach, A ;
Macete, E ;
Milman, J ;
Mandomando, I ;
Spiessens, B ;
Guinovart, C ;
Espasa, M ;
Bassat, Q ;
Aide, P ;
Ofori-Anyinam, O ;
Navia, MM ;
Corachan, S ;
Ceuppens, M ;
Dubois, MC ;
Demoitié, MA ;
Dubovsky, F ;
Menéndez, C ;
Tornieporth, N ;
Ballou, WR ;
Thompson, R ;
Cohen, J .
LANCET, 2004, 364 (9443) :1411-1420
[5]   Rapid antibody response after vaccination with a virosomal hepatitis A vaccine [J].
Ambrosch, F ;
Finkel, B ;
Herzog, C ;
Koren, A ;
Kollaritsch, H .
INFECTION, 2004, 32 (03) :149-152
[6]   Immunogenicity and protectivity of a new liposomal hepatitis A vaccine [J].
Ambrosch, F ;
Wiedermann, G ;
Jonas, S ;
Althaus, B ;
Finkel, B ;
Gluck, R ;
Herzog, C .
VACCINE, 1997, 15 (11) :1209-1213
[7]  
[Anonymous], 2008, WORLD MALARIA REPORT
[8]   Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique:: a double blind randomised controlled phase I/IIb trial [J].
Aponte, John J. ;
Aide, Pedro ;
Renom, Montse ;
Mandomando, Inacio ;
Bassat, Quique ;
Sacarlal, Jahit ;
Manaca, M. Nelia ;
Lafuente, Sarah ;
Barbosa, Arnoldo ;
Leach, Amanda ;
Lievens, Marc ;
Vekemans, Johan ;
Sigaugue, Betuel ;
Dubois, Marie-Claude ;
Demoitie, Marie-Ange ;
Sillman, Marla ;
Savarese, Barbara ;
McNeil, John G. ;
Macete, Eusebio ;
Ballou, W. Ripley ;
Cohen, Joe ;
Alonso, Pedro L. .
LANCET, 2007, 370 (9598) :1543-1551
[9]   Challenges for vaccination in the elderly [J].
Aspinall R. ;
Del Giudice G. ;
Effros R.B. ;
Grubeck-Loebenstein B. ;
Sambhara S. .
Immunity & Ageing, 4 (1)
[10]  
Aucouturier Jerome, 2002, Expert Rev Vaccines, V1, P111, DOI 10.1586/14760584.1.1.111